Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.6% – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares shot up 5.6% during trading on Thursday . The company traded as high as $83.98 and last traded at $84.05. 539,935 shares were traded during trading, a decline of 48% from the average session volume of 1,032,575 shares. The stock had previously closed at $79.61.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DNTH shares. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. William Blair reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Truist Financial raised their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Finally, Wells Fargo & Company assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $117.30.

Dianthus Therapeutics Stock Performance

The stock has a market cap of $3.67 billion, a PE ratio of -20.27 and a beta of 1.56. The business has a 50 day moving average price of $58.79 and a two-hundred day moving average price of $45.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The SEC filing for this sale provides additional information. Insiders have sold 200,430 shares of company stock worth $16,332,702 in the last ninety days. Company insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust raised its holdings in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $40,000. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics in the second quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics in the third quarter worth $64,000. Finally, Royal Bank of Canada raised its stake in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after buying an additional 542 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.